文献速递肝病

终末期肝病患者临终医疗资源利用与费用显著高于其他死亡患者

Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-02-10

基于加拿大安大略省行政数据库的回顾性队列研究显示,终末期肝病(ESLD)死者临终前一年中位费用为51235美元,高于无ESLD者的44456美元;临终前90天差异最明显,ESLD患者住院时间多4.7天,机构内死亡比值比为1.8,费用多4201美元。

要点

  • ESLD死者临终前一年中位费用51235美元,高于无ESLD死者的44456美元。
  • 临终前90天ESLD患者住院时间多4.7天(95%CI 4.3-5.1),费用多4201美元(95%CI 3384-5019)。
  • ESLD患者机构内死亡比值比为1.8(95%CI 1.7-1.9)。

核心结论

  • 在加拿大基于人群的研究中,ESLD患者临终医疗费用显著高于无ESLD死者,主要归因于临终前90天住院时间增加。

研究设计与样本

  • 研究为基于安大略省关联卫生行政数据库的回顾性队列研究,纳入2010年4月1日至2013年3月31日期间所有死者,比较ESLD患者与无ESLD患者的临终医疗利用与费用。

主要发现

  • ESLD死者中位死亡年龄为65岁(四分位距56-75岁),低于无ESLD死者的80岁(四分位距68-88岁)。
  • ESLD患者临终前一年中位费用为51235美元,高于无ESLD者的44456美元(P < .001)。
  • ESLD临终医疗中位费用为69040美元,高于无ESLD的59088美元(P < .001),并超过5种资源最密集慢性病中4种的相关费用。
  • 临终前90天,ESLD患者较无ESLD患者住院时间多4.7天(95%CI 4.3-5.1天)(P < .0001),机构内死亡比值比为1.8(95%CI 1.7-1.9)(P < .0001),费用多4201美元(95%CI 3384-5019美元)(P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with end-stage liver disease (ESLD) have progressively complex medical needs. However, little is known about their end-of-life health care utilization or associated costs. We performed a population-based study to evaluate the end-of-life direct utilization and costs for patients with ESLD among health care sectors in the province of Ontario. METHODS: We used linked Ontario health administrative databases to conduct a population-based retrospective cohort study of all decedents from April 1, 2010, through March 31, 2013. Patients with ESLD were compared with patients without ESLD with regard to total health care utilization and costs in the last year and last 90 days of life. RESULTS: The median age at death was significantly lower for ESLD decedents (65 y; interquartile range, 56-75 y) than for individuals without ESLD (80 y; interquartile range, 68-88 y). The median cost in the last year of life was significantly greater for patients with ESLD ($51,235 vs $44,456 without ESLD) (P < .001). Median ESLD end-of-life care costs also significantly exceeded those associated with 4 of the 5 most resource-intensive chronic conditions ($69,040 for ESLD vs $59,088 for non-ESLD) (P < .001). Cost differences were most pronounced in the final 90 days of life. During this period, patients with ESLD spent 4.7 more days in the hospital (95% CI, 4.3-5.1 d) than patients without ESLD (P < .0001), had significantly higher odds of dying in an institutional setting (odds ratio, 1.8; 95% CI, 1.7-1.9) (P < .0001), and incurred an additional $4201 in costs (95% CI, $3384-$5019; P < .0001). CONCLUSIONS: In a population-based study in Canada, we found that patients with ESLD incur significantly higher end-of-life care costs than decedents without ESLD, predominantly owing to increased time in the hospital during the final 90 days of life.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kelly EM, James PD, Murthy S, et al. Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. Clin Gastroenterol Hepatol. 2019. PMID: 30743007. doi:10.1016/j.cgh.2019.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。